Literature DB >> 16458393

Polar, functionalized guanine-O6 derivatives resistant to repair by O6-alkylguanine-DNA alkyltransferase: implications for the design of DNA-modifying drugs.

Dimitrios Pletsas1, Richard T Wheelhouse, Vassiliki Pletsa, Anna Nicolaou, Terence C Jenkins, Michael C Bibby, Soterios A Kyrtopoulos.   

Abstract

The protein O6-alkylguanine-DNA alkyltransferase (Atase) is responsible for the repair of DNA lesions generated by several clinically important anti-cancer drugs; this is manifest as active resistance in those cancer cell lines proficient in Atase expression. Novel O6-substituted guanine analogues have been synthesized, bearing acidic, basic and hydrogen bonding functional groups. In contrast to existing O6-modified purine analogues, such as methyl or benzyl, the new compounds were found to resist repair by Atase even when tested at concentrations much higher than O6-benzylguanine, a well-established Atase substrate active both in vitro and in vivo. The inactivity of the new purines as covalent substrates for Atase indicates that agents to deliver these groups to DNA would represent a new class of DNA-modifying drug that circumvents Atase-mediated resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458393     DOI: 10.1016/j.ejmech.2005.11.007

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  7 in total

1.  Alkyltransferase-like protein (Atl1) distinguishes alkylated guanines for DNA repair using cation-π interactions.

Authors:  Oliver J Wilkinson; Vitaly Latypov; Julie L Tubbs; Christopher L Millington; Rihito Morita; Hannah Blackburn; Andrew Marriott; Gail McGown; Mary Thorncroft; Amanda J Watson; Bernard A Connolly; Jane A Grasby; Ryoji Masui; Christopher A Hunter; John A Tainer; Geoffrey P Margison; David M Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-29       Impact factor: 11.205

2.  Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR.

Authors:  Elrashied A E Garelnabi; Dimitrios Pletsas; Li Li; Konstantinos Kiakos; Nazira Karodia; John A Hartley; Roger M Phillips; Richard T Wheelhouse
Journal:  ACS Med Chem Lett       Date:  2012-09-18       Impact factor: 4.345

3.  Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.

Authors:  Yulian P Ramirez; Ann C Mladek; Roger M Phillips; Mikko Gynther; Jarkko Rautio; Alonzo H Ross; Richard T Wheelhouse; Jann N Sakaria
Journal:  Mol Cancer Ther       Date:  2014-10-28       Impact factor: 6.261

4.  Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents.

Authors:  Lee Roy Morgan; Robert F Struck; William R Waud; Blaise LeBlanc; Andrew H Rodgers; Branko S Jursic
Journal:  Cancer Chemother Pharmacol       Date:  2009-03-03       Impact factor: 3.333

5.  Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53.

Authors:  Dimitrios Pletsas; Elrashied A E Garelnabi; Li Li; Roger M Phillips; Richard T Wheelhouse
Journal:  J Med Chem       Date:  2013-08-16       Impact factor: 7.446

6.  Glioblastoma multiforme therapy and mechanisms of resistance.

Authors:  Yulian P Ramirez; Jessica L Weatherbee; Richard T Wheelhouse; Alonzo H Ross
Journal:  Pharmaceuticals (Basel)       Date:  2013-11-25

7.  The medicinal chemistry of imidazotetrazine prodrugs.

Authors:  Catherine L Moody; Richard T Wheelhouse
Journal:  Pharmaceuticals (Basel)       Date:  2014-07-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.